$ tb500 --about
About Legit TB-500: who runs the readout, and what it is not
A checkable transcript of the TB-500 literature, sourced line by line. No clinic, no counter, no product.
What this project is
Legit TB-500 keeps a checkable transcript of the peer-reviewed literature on TB-500 and its parent protein, thymosin beta-4 — the record laid out plainly, presented as something to verify rather than to advertise. No clinic sits behind the terminal; no one here treats patients, prescribes, or gives medical advice. It makes nothing, sells nothing, and ships nothing. Its one function is to read the studies and transcribe them, every figure mapped to a numbered source.
The "legit" in the name is a reading posture, not a service. It means we treat the literature as something to verify rather than to advertise: every quantitative figure on the site maps to a numbered citation, and where a finding came from the full-length protein instead of the heptapeptide, we tag it as such rather than letting the ambiguity sell the compound. The terminal styling is the same idea made visual — the record presented as a checkable transcript.
What the modifier in our name does and does not claim
A name like this one occupies a position relative to the literature — the diligent, verify-the-source reader — and that is editorial framing, not a claim about services we offer. We do not run consultations, fill prescriptions, or provide treatment. There are no "our doctors" or "our pharmacists" here, because there is no clinic and no pharmacy behind this site; there is an editorial desk that reads studies and cites them.
That distinction matters most on the safety material. We surface the tumor/angiogenesis signal and the absence of controlled human data for the fragment plainly [13], not to discourage or encourage anything, but because an honest digest reports the gaps as carefully as the findings. The site is a reading of the record, full stop.
How we handle sources
Every page is built from a fixed source set: the structural and mechanistic studies of thymosin beta-4 [1][5], the preclinical wound, cardiac and neurological work [3][2][4], the single human Phase 1 study of the full-length protein [6], the angiogenesis literature [7][8], the 2026 Sports Medicine review of unapproved peptides [13], and FDA's own regulatory listings [16][17]. Nothing on the site is asserted without a traceable source, and claims the literature does not support are left out rather than softened into existence. The full list lives on the references page.